Erico Masala

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.

Journal: Blood advances

Published: September 22, 2020

Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?

Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?

Journal: Frontiers in oncology

Published: August 17, 2020

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Journal: The Lancet. Haematology

Published: February 09, 2018

Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

Journal: Haematologica

Published: May 20, 2017

The Leukemic Stem Cell Niche: Adaptation to "Hypoxia" versus Oncogene Addiction.

The Leukemic Stem Cell Niche: Adaptation to "Hypoxia" versus Oncogene Addiction.

Journal: Stem cells international

Published: February 16, 2017

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.

Journal: Oncotarget

Published: December 22, 2016

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.

Journal: Haematologica

Published: October 24, 2016

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Journal: Haematologica

Published: April 09, 2016

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Journal: The Journal of clinical investigation

Published: August 27, 2014

Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.

Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.

Journal: Epigenetics

Published: December 05, 2013

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Journal: Leukemia

Published: June 07, 2013

Assessment of congenital malformation risk in the progeny of the military and civilian personnel of the Salto di Quirra military base: preliminary results

Assessment of congenital malformation risk in the progeny of the military and civilian personnel of the Salto di Quirra military base: preliminary results

Journal: Giornale italiano di medicina del lavoro ed ergonomia

Published: February 15, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026